Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$950.87

12.27 (1.31%)

, CI

Cigna

$186.75

2.32 (1.26%)

10:41
09/28/17
09/28
10:41
09/28/17
10:41

Analyst sees Amazon disrupting retail pharmacy industry

In a research note this morning, Bernstein analyst Lance Wilkes told investors that he expects Amazon (AMZN) to enter the retail pharmacy industry, which leaves him increasingly concerned it will negatively impact Pharmacy Benefit Manager, or PBM, earnings levers. AMAZON TO DISRUPT RETAIL PHARMACY: Amazon will enter the retail pharmacy industry, especially because it is a large and disruptable market, Bernstein's Wilkes told investors, adding that he believes Amazon is well positioned to address/impact the major customer issues in this market. Wilkes sees the retail pharmacy sector as a $300B market with potential margins in the high single digits, and believes the barriers to online/mail adoption have been poor user interface and insufficient cost savings to motivate consumers to switch to online/mail. Amazon can disrupt retail pharmacy given the operating expense efficiencies of a centralized online model, he argued, while noting that the major advantages come from eliminating 70,000 retail locations, which could be replaced by automated distribution centers with efficient pharmacist oversight. Further, the analyst pointed out that Amazon could further lower prices if it is willing to sacrifice margin to gain scale. In terms of strategic options, Wilkes argued that the e-commerce giant could either partner with large PBMs, such as UnitedHealth's (UNH) OptumRx or Cigna (CI), or disrupt both the PBM and retail pharmacy model through buying a smaller transparent PBM or creating a carve-out online option for MCOs and employers. The analyst believes OptumRx, along with other MCO owned PBMs, are the most logical partner, and thinks MedImpact or RiteAid's (RAD) EnvisionRx are the most logical targets. Additionally, Wilkes noted that the innovation of utilizing Amazon would be consistent with UnitedHealth's innovative approaches in other consumer engagement areas. Overall, the analyst sees Amazon's entry as negative for independent pharmacies, somewhat negative for national pharmacies and distributors, and a long term negative for PBMs. Publicly traded owners of PBMs include Express Scripts (ESRX), UnitedHealth, and CVS Health (CVS). PERRIGO OPPORTUNITY: Commenting on the specialty pharmaceuticals sector, Morgan Stanley analyst David Risinger told investors in a research note of his own that after thinking through Perrigo's (PRGO) opportunity to grow with Amazon, he does not expect much of an incremental sales opportunity. Online purchases will likely cannibalize existing Perrigo sales via traditional retailers, he argued. Amazon currently sells Perrigo's GoodSense low-cost brand and Risinger sees it as possible that Amazon eventually develops its own brand and sources private label products from Perrigo and others, which would also likely cannibalize GoodSense. The analyst reiterated an Equal Weight rating on Perrigo's shares. PRICE ACTION: In morning trading, shares of Amazon are fractionally up to $950.90. Shares of Express Scripts and UnitedHealth are also fractionally up to $63.19 and $194.96, respectively, while CVS is fractionally down to $81.21.

AMZN

Amazon.com

$950.87

12.27 (1.31%)

CI

Cigna

$186.75

2.32 (1.26%)

CVS

CVS Health

$81.13

-0.34 (-0.42%)

RAD

Rite Aid

$2.02

-0.26 (-11.40%)

UNH

UnitedHealth

$195.10

0.61 (0.31%)

ESRX

Express Scripts

$62.96

-0.09 (-0.14%)

PRGO

Perrigo

$83.94

-1.2 (-1.41%)

  • 28

    Sep

  • 28

    Sep

  • 03

    Oct

  • 04

    Oct

  • 04

    Oct

  • 05

    Oct

  • 08

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 25

    Oct

AMZN Amazon.com
$950.87

12.27 (1.31%)

09/27/17
WBLR
09/27/17
NO CHANGE
WBLR
Outperform
Kornit Digital long-term opportunity remains unchanged, says William Blair
William Blair analyst Brian Drab believes Kornit Digital's (KRNT) shortfall in Q3 is a function of timing and that the company's fundamental long-term opportunity remains unchanged. The valuation multiple in the near term, however, will be "tempered given volatility associated with customer concentration," Drab tells investors in a research note. The analyst thinks Amazon (AMZN) is the customer experiencing the permitting issue, which he notes management expects to be resolved in the next few months. He keeps an Outperform rating on the shares.
09/28/17
BERN
09/28/17
NO CHANGE
BERN
Amazon will enter retail pharmacy industry, says Bernstein
Bernstein analyst Lance Wilkes thinks Amazon will enter the retail pharmacy industry, especially because it is a large and disruptable market. The analyst believes Amazon is well positioned to address/impact the major customer issues in this market, and expects it will need to partner with or acquire a PBM to drive volume growth. Wilkes is also increasingly concerned that Amazon's entry will negatively impact PBM earnings levers.
09/28/17
MSCO
09/28/17
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says Perrigo opportunity at Amazon 'more hype' than sales driver
Morgan Stanley analyst David Risinger believes online sales are unlikely to drive higher net revenue for Perrigo (PRGO) in the U.S. because such purchases will likely cannibalize existing sales via traditional brick and mortar retailers. Amazon (AMZN) currently sells Perrigo's GoodSense low-cost brand and Risinger sees it as possible that Amazon eventually develops its own brand and sources private label products from Perrigo and others, but this would also likely cannibalize GoodSense, he tells investors. The analyst, who noted "this is not a negative stock call," keeps an Equal Weight rating on Perrigo.
09/28/17
JMPS
09/28/17
NO CHANGE
Target $1125
JMPS
Outperform
JMP says Amazon new products significantly expand connected home presence
JMP Securities analyst Ronald Josey said Amazon significantly expanded its connected home presence with its announcement of new Alexa products yesterday, including the new Echo Plus, Echo Spot and lower-cost revamped Echo. The analyst, who was impressed with the expanded capabilities of the products, noted the second generation Echoes are now 44% cheaper, which he believes should lead to greater adoption. Josey keeps an Outperform rating and $1,125 price target on Amazon shares.
CI Cigna
$186.75

2.32 (1.26%)

07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
06/16/17
06/16/17
NO CHANGE

Leerink reiterates view that Cigna could bid for Humana
Leerink analyst Ana Gupte reiterated his views that Cigna (CI) could make a bid Humana (HUM) following Cigna's disclosure that 60% of its Medicare Advantage plans will be in 4-STAR rated plans. The announcement is most positive for Humana (HUM) which is the largest pure play Medicare Advantage name, but also paves the way for Cigna to potentially dievest its legacy HS Medicare Advantage book and bid for Humana.
CVS CVS Health
$81.13

-0.34 (-0.42%)

08/28/17
NEED
08/28/17
NO CHANGE
NEED
Amazon, Whole Foods combined company not an incremental competitor, says Needham
Needham analyst Kevin Caliendo notes that drug retailers were weak after Amazon (AMZN) said it would provide its Prime members enhanced benefits while shopping at newly acquired Whole Foods (WFM) and cut prices on certain household staple items inside the grocer. While the analyst understands the Amazon threat will remain for the drug retailers and pharma supply chain, he believes the news should have no material impact on revenues or profits at CVS Health (CVS) and Walgreens Boots Alliance (WBA). Caliendo expects that Amazon will continue to try and lever its website and Whole Foods store locations to increase traffic, but he does not yet see the combined company as an incremental competitor beyond what each did separately.
09/14/17
LEER
09/14/17
NO CHANGE
LEER
Minimal hurricane exposure for pharma supply chain, says Leerink
Leerink analyst David Larsen sees less than 1% impact to revenues and earnings to companies in his coverage from Hurricane Harvey and Irma and believes any effects will be viewed as one-time in nature. The analyst notes that "the percentage of state impacted" and "days of impact" are particularly challenging variables in his model to estimate, but based on various assumptions he believes the hurricanes will prove to be a minor event for Express Scripts (ESRX), AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK). Nonetheless, Larsen says pharmacy retailers Walgreens Boots Alliance (WBA) and CVS Health (CVS) may face some store closures and possible damage costs.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Outperform
CVS Health initiated with an Outperform at RBC Capital
RBC Capital analyst George Hill started coverage of CVS with a $95 price target and an Outperform rating. He thinks that the company "could transform itself" by merging with a health insurance company, although he says that the chances of such a deal are "low." He estimates that such a deal could increase the company's EPS by over 10% and cause its multiple to rise by 200%-400%. Hill says that the stock's valuation is attractive even if the company does not make a deal.
09/19/17
09/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Underperform at Jefferies. 2. DowDuPont (DWDP) initiated with a Buy at Argus. 3. Intuit (INTU) initiated with an Outperform at William Blair. 4. CVS Health (CVS) initiated with an Outperform at RBC Capital. 5. athenahealth (ATHN) initiated with a Sector Perform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RAD Rite Aid
$2.02

-0.26 (-11.40%)

09/11/17
LOOP
09/11/17
INITIATION
Target $2.5
LOOP
Hold
Rite Aid initiated with a Hold at Loop Capital
Loop Capital analyst Andrew Wolf started Rite Aid (RAD) with a Hold rating and $2.50 price target, stating that he views the company's re-worked store sale to Walgreens (WBA) as a "re-launch of Rite Aid's turnaround efforts" and believes it lacks intermediate term earnings visibility.
08/23/17
UBSW
08/23/17
NO CHANGE
Target $96
UBSW
Buy
Walgreens Boots Alliance should see upside from new Rite Aid deal, says UBS
UBS analyst Michael Cherny said his review of the new Walgreens Boots Alliance (WBA) deal with Rite Aid (RAD) would provide immediate accretion from synergy opportunities if the deal is approved. He believes it can provide meaningful upside to earnings as well as remove the lack of clarity on capital deployment-driven earnings contribution. Thus, he sees the shares as having a positive risk/reward skew. Cherny reiterated his Buy rating and lowered his price target to $96 from $97 on Walgreens shares.
09/12/17
09/12/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with an Outperform at Macquarie. 2. Bunge (BG) initiated with a Neutral at Baird. 3. Rite Aid (RAD) initiated with a Hold at Loop Capital. 4. Nike (NKE) was initiated with an Outperform at Bernstein, while Under Armour (UA) was initiated with an Underperform. 5. Houlihan Lokey (HLI) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Rite Aid initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Rite Aid with a $2.50 price target and a Sector Perform rating.
UNH UnitedHealth
$195.10

0.61 (0.31%)

08/29/17
PIPR
08/29/17
NO CHANGE
Target $54.29
PIPR
Neutral
Piper says Advisory Board deal should be marginally accretive to UnitedHealth
Piper Jaffray analyst Sean Wieland said Advisory Board's (ABCO) deal to merge its healthcare business with United Healthcare's (UNH) OptumInsights should be marginally accretive to UnitedHealth and add to his confidence in his FY18 OptumInsights growth estimates. He keeps a Neutral rating on Advisory Board shares and raised his price target on the stock to $54.29 from $51 to reflect the combined estimated amount being paid to shareholders by Optum and Vista Equity, the buyers of Advisory's education business.
08/11/17
COWN
08/11/17
NO CHANGE
Target $220
COWN
Outperform
UnitedHealth price target raised to $220 from $175 at Cowen
Cowen analyst Christine Arnold raised her price target on UnitedHealth to $220 from $175. The analyst believes the company can achieve its long-term growth targets in 2018, citing Medicare Advantage enrollment growth, operating efficiencies, commercial market penetration, and OptumRx and OptumInsight earnings gains. Arnold reiterated her Outperform rating on UnitedHealth shares.
08/16/17
PIPR
08/16/17
NO CHANGE
PIPR
Overweight
UnitedHealth made 'solid choice' in new CEO, says Piper Jaffray
Piper Jaffray analyst Sarah James views UnitedHealth's promotion of David Wichmann as a "solid choice and not a surprise." The analyst expects business as usual for the company as it continues to push into technology including artificial intelligence. She has an Overweight rating on the shares.
08/30/17
ADAM
08/30/17
DOWNGRADE
Target $54
ADAM
Hold
The Advisory Board downgraded to Hold from Buy at Canaccord
Canaccord analyst Richard Close downgraded The Advisory Board (ABCO) to Hold from Buy based on the announced transaction to split the company by selling the Healthcare business to UnitedHealth's (UNH) Optum unit and the Education Business to Vista Equity Partners. Close lowered his price target to $54.29 on Advisory Board shares.
ESRX Express Scripts
$62.96

-0.09 (-0.14%)

06/27/17
BARD
06/27/17
NO CHANGE
Target $20
BARD
Outperform
Diplomat Pharmacy and entire supply chain have reimbursement risk, says Baird
Baird analyst Eric Coldwell noted Diplomat Pharmacy (DPLO) shares were lower yesterday based on a competitor's research note that suggested Express Scripts (ESRX) was cutting reimbursement in certain commercial plans and is kicking the tires on a DIR rollout in Part D. The analyst believes that would be not only negative for Diplomat but for all in the supply chain. The fact that others were not hit as hard is confusing to Coldwell, but he hopes for clarification from the company's IR day tomorrow. Coldwell maintained his Outperform rating and $20 price target on Diplomat Pharmacy shares.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Express Scripts initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Express Scripts (ESRX) with a $68 price target and a Sector Perform rating. The analyst says that the company "faces an uncertain future" in the wake of the loss of its deal with Anthem ( ANTM), as he believes that it will have difficulty generating operating profit growth without Anthem.
PRGO Perrigo
$83.94

-1.2 (-1.41%)

09/14/17
DBAB
09/14/17
NO CHANGE
Target $95
DBAB
Buy
Perrigo price target raised to $95 from $88 at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert raised his price target for Perrigo to $95 saying that while the company's turnaround has taken longer than expected, "a recovery in sentiment appears to be well underway." Management has set appropriate expectations and is as confident as ever that they can continue to deliver, Gilbert tells investors in a research note. He thinks the shares can continue to "grind higher" if Perrigo meets/beats its forecasts. Gilbert keeps a Buy rating on Perrigo.
09/13/17
ADAM
09/13/17
NO CHANGE
Target $100
ADAM
Buy
Perrigo price target raised to $100 from $88 at Canaccord
Canaccord analyst Dewey Steadman raised his price target on Perrigo to $100 from $88 following meetings with management. The analyst said the company remains well positioned as a hybrid consumer/generic play and believes its management leadership is impressive. Steadman reiterated his Buy rating on Perrigo shares.
09/12/17
CANT
09/12/17
NO CHANGE
Target $107
CANT
Overweight
Perrigo price target raised to $107 from $93 at Cantor
Cantor Fitzgerald analyst Louise Chen raised her price target on Perrigo to $107 from $93 after she left her meeting with the company's CEO and CFO thinking that things are better than she'd anticipated. The analyst, who thinks Perrigo can return to durable and consistent growth in 2018 and beyond, keeps an Overweight rating on the stock.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.